Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Enthera Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Biofit 2020

              Participation Not Confirmed

              Update your events

              Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD

              Contact the Supplier

              Lead Product(s): Ent001

              Therapeutic Area: Endocrinology Product Name: Ent001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sofinnova Partners

              Deal Size: $33.1 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 28, 2020

              Details:

              Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.

              PharmaCompass__DigitalAd